Evidence map›Paper›PMID 35050419›Full record

ArticleClinical rheumatology2022

Exploring cannabis use and perspectives among psoriatic disease patients.

Jackie Tsang, Orli Silverberg, Rohan Machhar, Remy Pollock, Daniel Pereira, Mitchell Sutton, Dafna D Gladman, Cheryl F Rosen

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jackie TsangFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
Orli SilverbergFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
Rohan MachharPsoriatic Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Remy PollockPsoriatic Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
Daniel PereiraPsoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, ON, Canada.
Mitchell SuttonPsoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, ON, Canada.
Dafna D GladmanFaculty of Medicine, University of Toronto, Toronto, ON, Canada. dafna.gladman@utoronto.ca.
Cheryl F RosenFaculty of Medicine, University of Toronto, Toronto, ON, Canada.
University Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the correlation between cannabis use and psoriatic disease severity, health-related quality of life, pain, psychosocial outcomes, and cytokine levels in psoriasis (PsC) and psoriatic arthritis (PsA) patients.

methodsPsC and PsA patients enrolled in the International Psoriasis and Arthritis Research Team (IPART) program were surveyed on cannabis use and were asked to provide a serum and urine sample. Demographic and clinical variables were compared between users and non-users using Student's t-test or Mann-Whitney U test for continuous variables, and chi-square or Fisher's exact test for categorical variables.

resultsOf 151 respondents, 30% reported current cannabis use within the last year. Compared to non-users, cannabis users were younger and had a shorter PsA duration and poorer mental health as measured by the SF-36. Other measures of health-related quality of life and pain were comparable between the groups. Respondents' primary perceived benefits of cannabis use were aid in sleep and arthritis pain relief, but there was no difference in pain between users and non-users. No THC was detected in the urine of non-users while users had a mean level of 19.6 ng/ml. Serum IL-23 levels were statistically significantly higher in non-users than in users.

conclusionA third of the patients used cannabis within the past year, and 54.3% of users reported the use of cannabis for arthritis pain relief. However, there was no difference in pain scores. Comprehensive education for providers on the current body of evidence and further studies on cannabis use and outcomes in psoriatic disease are needed. Key Points • A third of patients with psoriatic arthritis have used cannabis in the past year. • Most used it for better sleep and control of pain. • There was no difference in pain scores between users and non-users. • IL-23 levels were significantly higher in non-users.

Indexed as

Arthritis, PsoriaticCannabisPsoriasisAnalgesicsHumansInterleukin-23MalePainProstate-Specific AntigenQuality of LifeAnalgesicsInterleukin-23Prostate-Specific AntigenCannabisIL-23PainPsoriasisPsoriatic arthritis

Identifiers

PMID35050419
OpenAlexW4206228534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.